Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2002 Oct;57(10):865–868. doi: 10.1136/thorax.57.10.865

Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma

G Currie 1, S Fowler 1, A Wilson 1, E Sims 1, L Orr 1, B Lipworth 1
PMCID: PMC1746197  PMID: 12324672

Abstract

Background: With the transition to hydrofluoroalkane-134a propellants in metered dose inhalers, it is important to consider the efficacy and safety profiles of formulations containing inhaled corticosteroids. We examined the airway and systemic effects of hydrofluoroalkane-134a fluticasone propionate (FLU-HFA) and beclomethasone dipropionate (BEC-HFA) at recommended labelled doses.

Methods: Twenty mild to moderate asthmatics were randomised in crossover fashion to receive 6 weeks of 500 µg/day followed by 1000 µg/day FLU-HFA and BEC-HFA. Measurements were made at baseline after placebo run in and washout, and after each randomised treatment. The primary airway outcome for benefit was the dose of methacholine provoking a fall in forced expiratory volume in 1 second (FEV1) of 20% or more (methacholine PD20) and for systemic adverse effects was overnight urinary cortisol/creatinine (OUCC).

Results: For mean responses, both doses of BEC-HFA and FLU-HFA produced significant improvements in PD20 compared with baseline. The improvement was not significantly greater with 1000 µg/day FLU-HFA versus BEC-HFA, a 1.69 fold difference (95% CI 0.94 to 3.04). Both doses of BEC-HFA but not FLU-HFA caused significant suppression of OUCC compared with baseline, with significantly (p<0.05) lower values at 1000 µg/day for BEC-HFA versus FLU-HFA (1.97 fold difference (95% CI 1.28 to 3.02)).

Conclusion: There was no difference in the airway and systemic effects in patients with mild to moderate asthma between FLU-HFA and BEC-HFA at a dose of 500 µg/day. At 1000 µg/day there was increased systemic bioactivity with BEC-HFA compared with FLU-HFA, without any gain in airway efficacy.

Full Text

The Full Text of this article is available as a PDF (115.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beach J. R., Young C. L., Avery A. J., Stenton S. C., Dennis J. H., Walters E. H., Hendrick D. J. Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response. Thorax. 1993 Mar;48(3):239–243. doi: 10.1136/thx.48.3.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Broide J., Soferman R., Kivity S., Golander A., Dickstein G., Spirer Z., Weisman Y. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab. 1995 Apr;80(4):1243–1246. doi: 10.1210/jcem.80.4.7714095. [DOI] [PubMed] [Google Scholar]
  3. Brutsche M. H., Brutsche I. C., Munawar M., Langley S. J., Masterson C. M., Daley-Yates P. T., Brown R., Custovic A., Woodcock A. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000 Aug 12;356(9229):556–561. doi: 10.1016/S0140-6736(00)02581-2. [DOI] [PubMed] [Google Scholar]
  4. Busse W. W., Chervinsky P., Condemi J., Lumry W. R., Petty T. L., Rennard S., Townley R. G. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):457–463. doi: 10.1016/S0091-6749(98)70353-7. [DOI] [PubMed] [Google Scholar]
  5. Cripps A., Riebe M., Schulze M., Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000 Jun;94 (Suppl B):S3–S9. [PubMed] [Google Scholar]
  6. Dempsey Owen J., Kennedy Gwen, Lipworth Brian J. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol. 2002 Jan;109(1):68–74. doi: 10.1067/mai.2002.120559. [DOI] [PubMed] [Google Scholar]
  7. Fowler S. J., Orr L. C., Wilson A. M., Sims E. J., Lipworth B. J. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Br J Clin Pharmacol. 2001 Jul;52(1):93–95. doi: 10.1046/j.0306-5251.2001.bjcp.1399.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harrison T. W., Wisniewski A., Honour J., Tattersfield A. E. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax. 2001 Mar;56(3):186–191. doi: 10.1136/thorax.56.3.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Holt S., Suder A., Weatherall M., Cheng S., Shirtcliffe P., Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001 Aug 4;323(7307):253–256. doi: 10.1136/bmj.323.7307.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kharitonov S. A., Chung K. F., Evans D., O'Connor B. J., Barnes P. J. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1773–1780. doi: 10.1164/ajrccm.153.6.8665033. [DOI] [PubMed] [Google Scholar]
  11. Kunka R., Andrews S., Pimazzoni M., Callejas S., Ziviani L., Squassante L., Daley-Yates P. T. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med. 2000 Jun;94 (Suppl B):S10–S16. [PubMed] [Google Scholar]
  12. Lipworth B. J., Jackson C. M. Influences on plasma cortisol of different formulations of beclomethasone dipropionate. Br J Clin Pharmacol. 2000 Oct;50(4):381–381. doi: 10.1046/j.1365-2125.2000.00266.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lipworth B. J., Jackson C. M. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol. 1999 Dec;48(6):866–868. doi: 10.1046/j.1365-2125.1999.00098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. McIntyre H. D., Mitchell C. A., Bowler S. D., Armstrong J. G., Wooler J. A., Cowley D. M. Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens. Thorax. 1995 Dec;50(12):1280–1284. doi: 10.1136/thx.50.12.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nielsen L. P., Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000 Dec;162(6):2053–2057. doi: 10.1164/ajrccm.162.6.9912072. [DOI] [PubMed] [Google Scholar]
  16. Tonnel A. B., Bons J., Legendre M., Prud'Homme A., Bugnas B., Evano-Celli I., Stuart A. M. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Respir Med. 2000 Jun;94 (Suppl B):S29–S34. [PubMed] [Google Scholar]
  17. Weiner P., Berar-Yanay N., Davidovich A., Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest. 1999 Oct;116(4):931–934. doi: 10.1378/chest.116.4.931. [DOI] [PubMed] [Google Scholar]
  18. Welch M., Bernstein D., Gross G., Kane R. E., Banerji D. A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. Chest. 1999 Nov;116(5):1304–1312. doi: 10.1378/chest.116.5.1304. [DOI] [PubMed] [Google Scholar]
  19. Wilson A. M., Lipworth B. J. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax. 1999 Jan;54(1):20–26. doi: 10.1136/thx.54.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wilson A. M., Lipworth B. J. Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med. 2000 Mar;108(4):269–275. doi: 10.1016/s0002-9343(99)00435-0. [DOI] [PubMed] [Google Scholar]
  21. Wilson A. M., Sims E. J., Orr L. C., Lipworth B. J. Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet. 1999 Oct 16;354(9187):1357–1358. doi: 10.1016/S0140-6736(99)03581-3. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES